Notable Labs, Ltd. financial data

Symbol
NTBL on Nasdaq
Industry
Pharmaceutical Preparations
Location
320 Hatch Drive, Foster City, CA
State of incorporation
Israel
Fiscal year end
December 31
Former names
Vascular Biogenics Ltd. (to 10/12/2023)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 531 % +60.8%
Debt-to-equity 28.6 %
Return On Equity -80.8 % -581%
Return On Assets -62.9 % -247%
Operating Margin -162K % -4036%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.66M shares -87.6%
Common Stock, Shares, Outstanding 9.66M shares -86.3%
Entity Public Float 15.8M USD -83.2%
Common Stock, Value, Issued 849K USD +385%
Weighted Average Number of Shares Outstanding, Basic 9.46M shares +874%
Weighted Average Number of Shares Outstanding, Diluted 9.46M shares +874%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2K USD
Research and Development Expense 2.35M USD +123%
General and Administrative Expense 9.53M USD +93.4%
Operating Income (Loss) -15.4M USD -1129%
Nonoperating Income (Expense) 4.83M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -10.5M USD -148%
Earnings Per Share, Basic 5.62 USD/shares +84.5%
Earnings Per Share, Diluted 5.62 USD/shares +84.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.09M USD -83.1%
Marketable Securities, Current 0 USD
Cash, Cash Equivalents, and Short-term Investments 24.3M USD -29.6%
Accounts Receivable, after Allowance for Credit Loss, Current 184K USD
Other Assets, Current 171K USD +15.5%
Assets, Current 6.98M USD -71.6%
Property, Plant and Equipment, Net 346K USD
Operating Lease, Right-of-Use Asset 1.47M USD
Other Assets, Noncurrent 104K USD
Assets 11M USD -55.4%
Employee-related Liabilities, Current 2.21M USD +352%
Accrued Liabilities, Current 172K USD
Contract with Customer, Liability, Current 482K USD -35.9%
Liabilities, Current 2.52M USD -52.5%
Operating Lease, Liability, Noncurrent 1.03M USD
Other Liabilities, Noncurrent 220K USD +41.9%
Liabilities 3.82M USD -29.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 116K USD
Retained Earnings (Accumulated Deficit) -91.3M USD +69.4%
Stockholders' Equity Attributable to Parent 7.19M USD
Liabilities and Equity 11M USD -55.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.56M USD -21.8%
Net Cash Provided by (Used in) Financing Activities -19K USD -100%
Net Cash Provided by (Used in) Investing Activities -6M USD
Common Stock, Shares Authorized 34.3M shares -82.9%
Common Stock, Shares, Issued 9.66M shares -86.3%
Common Stock, Par or Stated Value Per Share 0.35 ILS/shares +3400%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.09M USD +116%
Deferred Tax Assets, Valuation Allowance 86M USD +333%
Deferred Tax Assets, Gross 86M USD +333%
Operating Lease, Liability 1.49M USD
Depreciation 0 USD
Payments to Acquire Property, Plant, and Equipment 6K USD +50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.28M USD -53.7%
Lessee, Operating Lease, Liability, to be Paid 1.63M USD
Property, Plant and Equipment, Gross 2.41M USD
Operating Lease, Liability, Current 467K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 569K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 552K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure +50%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 140K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 239K USD
Deferred Tax Assets, Operating Loss Carryforwards 78.7M USD +411%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 84K USD -55.3%
Share-based Payment Arrangement, Expense 155K USD -23.3%
Interest Expense 108K USD +36.7%